Director/PDMR Shareholding

Bioventix plc

(“Bioventix” or the “Company”)

Director dealing

Bioventix plc (AIM: BVXP) was notified today that on 19 October 2015, Ian Nicholson, Chairman of the Company, and connected persons, sold 5,000 ordinary shares of 5 pence each (“Ordinary Shares”) at a price of 1,115 pence per Ordinary Share (the “Sale”). Following the Sale, Mr Nicholson holds 27,000 Ordinary Shares (13,000 of which are held in the name of his wife), representing approximately 0.5% of the issued share capital of the Company.

For further information please contact:

Bioventix plc Peter Harrison	Chief Executive Officer	Tel: [phone]
finnCap Ltd Geoff Nash/Simon Hicks Steve Norcross	Corporate Finance Corporate Broking	Tel: [phone]

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.